No articles this week

INFERTILITY AND MENTAL HEALTH
No articles this week

PSYCHIATRIC ILLNESS DURING PREGNANCY
No articles this week

MEDICATIONS AND PREGNANCY

• Toward Precision Dosing of Lamotrigine During Pregnancy: Physiologically Based Pharmacokinetic Modeling and Simulation.
  Qian Y, Wu W, Ke C, Liu S, Chen J, Chen Y, Guo X, Lin W. CPT Pharmacometrics Syst Pharmacol. 2025 May;14(5):929-940.
  For lamotrigine, the area under the steady-state concentration-time curve (AUC) decreased by 66.5%, 71.1%, and 81.2% during early, mid, and late pregnancy.

• Changes in S-Citalopram Plasma Concentrations Across Pregnancy and Postpartum.
  Stika CS, Avram MJ, George AL Jr, Yang A, Ciolino JD, Jeong H, Venkataramanan R, Caritis SN, Costantine MM, Wisner KL. Clin Pharmacol Ther. 2025 Jul;118(1):106-117.
  Without dose adjustment, people with intermediate or poor CYP2C19 activity may be at risk for subtherapeutic S-citalopram concentrations during pregnancy.

• Prevalence Trends and Patterns of Perinatal ADHD Stimulant Medication Use in British Columbia, Canada.
  Nitschke A, Salmanpour A, Kaur P, do Valle HA, Elwood C, Gadermann A, Guhn M, Hippman C, Ip A, Karim JL, Oberlander TF, Socha PM, Hanley GE. Pharmacoepidemiol Drug Saf. 2025 Apr;34(4):e70129.
  Among those who used stimulant medications within 1 year preconception, 77% discontinued treatment before or during pregnancy. Use increased within 12 months postpartum but remained 45% lower than preconception levels.

POSTPARTUM PSYCHIATRIC ILLNESS

• Esketamine reduces the risk of postpartum depression in women undergoing cesarean section: A systematic review and meta-analysis.
  Frivaldszky L, L?rincz K, Hoferica J, Hegyi P, Ács N, Melczer Z, Fehérvári P, Keszthelyi M. J Psychiatr Res. 2025 Mar;183:164-173.
  Esketamine administered at delivery was associated with a lower rate of PPD at postpartum days 3–7 and 28–42. It was also associated with significantly lower EPDS scores in the early postpartum period.

MEDICATIONS AND BREASTFEEDING
No articles this week

PERINATAL SUBSTANCE USE

• Racial and Ethnic Inequities in the Receipt of Medications to Treat Opioid Use Disorder Among Pregnant People: A Meta-analysis.
  Gerdts G, Sale K, Raynor P, Schiff DM, Terplan M, Bush E, Nidey N. J Addict Med. 2025 Jul-Aug;19(4):437-445.
  Use of medications for OUD was significantly less common among Black (OR 0.35) and Hispanic (OR 0.60) pregnant people compared to White counterparts.

• Buprenorphine-naloxone versus buprenorphine for opioid use disorder during pregnancy: A systematic review and meta-analysis.
  de Lima FR, Molino GOG, Gallo Ruelas M, Barbosa EC, Silva PHCMD, Guimarães FBM, Petrucci ABC, Silva GHSD, Sbardelotto ÂEE, Lança SB, Garbacka A. Drug Alcohol Depend. 2025 Jun 1;271:112632.
  Pregnant people treated with buprenorphine-naloxone had neonates with a lower risk of small for gestational age and NAS.

• Weighing Risks and Benefits: Patient Perceptions on Using Medications for Opioid Use Disorder During and After Pregnancy.
  Eitel AE, Mujica C, Hayes MA, Guille C, McRae-Clark A, Witcraft SM. Subst Use Addctn J. 2025 Jul;46(3):665-674.
  Participants were motivated toward MOUD in pregnancy for maternal and fetal benefits but noted drawbacks including neonatal withdrawal. Postpartum, motivations shifted toward mental health and parenting, with some anticipating tapering off MOUD.

• Inpatient Buprenorphine Initiation for Pregnant Patients.
  Lee A, Stokes K, Goodman D, Low J, Johnson A, Blatman R. Obstet Gynecol. 2025 Apr;145(4):e136.
  This project provides resources and toolkits to support inpatient buprenorphine initiation for pregnant patients with OUD.

• Prenatal opioid use disorder and child protective service involvement: Does consistent treatment matter?
  Wang Y, Ehrenthal D, Bo A, Berger L. J Subst Use Addict Treat. 2025 May;172:209681.
  Consistent MOUD treatment (?5 consecutive months) during pregnancy was associated with lower child removal risk compared to intermittent treatment.

• Split-dosing of Methadone During Pregnancy and Postpartum Period: A Systematic Review of Outcomes.
  Khan NZ, Hand DJ, Qian E, Conklin JL, Johnson E, McCarthy JJ, Ramage M, Rudolf V, Schauberger C, Stoller KB, Terplan M, Jones HE.
  Pregnancy substantially alters methadone metabolism. Evidence suggests split-dosing compared to once-daily dosing is associated with better maternal and neonatal outcomes.

MATERNAL MENTAL HEALTH AND CHILD OUTCOMES

• Prenatal exposure to psychotropics and analgesics on cognitive, linguistic and educational outcomes – a scoping review with focus on validity and reliability of outcome measures.
  Reddy AS, Fawad F, Leite MA, Olstad EW, Gervin K, Kanduri C, Sandve GK, Brandlistuen R, Lupattelli A, von Koss Torkildsen J, Nordeng HME. BMC Pregnancy Childbirth. 2025 Mar;25(1):234.
  With the exception of valproate, limited evidence exists on the impact of prenatal psychotropic/analgesic exposure on offspring cognitive, linguistic, and educational outcomes.

• Gestational Exposure to Valproate and Autism Spectrum Disorder or Attention-Deficit/Hyperactivity Disorder in Offspring: Systematic Review and Meta-Analysis.
  Andrade C, Varadharajan N, Bascarane S, Kale A, Gnanadhas J, Menon V. Acta Psychiatr Scand. 2025 Jun;151(6):668-679.
  Gestational exposure to valproate was linked to increased ASD and ADHD risk, especially at doses above 1000 mg/day.

MENOPAUSE AND MENTAL HEALTH
No articles this week

OTHER TOPICS IN WOMEN’S MENTAL HEALTH

• Discordant Sibling Pair Comparisons in Observational Studies: A Research Design Simply Explained.
  Andrade C. J Clin Psychiatry. 2025 Mar;86(2).
  Explains the design of sibling comparison studies as a method to account for shared genetic and environmental confounders in observational research.